Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821459 | 1.00 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19821468 | 1.00 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19821469 | 0.83 | EP300 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19821470 | 0.83 | EP300 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL668867 | 0.82 | TSHR (0.54) | KMT2ATSHRMEN1LMNATP53 | |
| SCHEMBL19821465 | 0.81 | MEN1 (0.50) | KMT2AHSP90AA1TSHRMEN1 | |
| SCHEMBL19821460 | 0.81 | MEN1 (0.50) | KMT2AHSP90AA1TSHRMEN1 | |
| SCHEMBL19821458 | 0.81 | MEN1 (0.50) | KMT2AHSP90AA1TSHRMEN1 | |
| SCHEMBL7760951 | 0.80 | KMT2A (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7754584 | 0.80 | KMT2A (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030213-A1 | BLOCK CO-POLY(METAL ORGANIC NANOSTRUCTURES) (BCPMONS) AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030213-A1 | BLOCK CO-POLY(METAL ORGANIC NANOSTRUCTURES) (BCPMONS) AND USES THEREOF | MB, EBPL, POF1B | CA12 81/4885CA1 288/4885CA2 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.